摘要
目的观察早期应用依达拉奉对rt-PA静脉溶栓治疗急性脑梗死效果的影响。方法将急性脑梗死患者160例按信封法随机分为对照组和观察组,每组80例,对照组入院即给予胞二磷胆碱治疗,观察组入院即给予依达拉奉治疗,且两组均接受rt-PA静脉溶栓治疗。治疗前及治疗2周后对患者进行NIHSS评分及Barthel指数(BI)量表评分;检测患者血浆同型半胱氨酸(Hcy)、S100β蛋白、内皮素-1(ET-1)水平;观察两组治疗过程中出血性转化(HT)发生情况及不良反应发生情况。结果治疗2周后,观察组较对照组NIHSS评分明显降低(P<0.05),BI评分明显升高(P<0.05);治疗2周后,观察组较对照组Hcy、S100β蛋白、ET-1水平均明显降低(P<0.05);治疗2周后,观察组较对照组HT发生率明显降低(P<0.05);两组不良反应发生率比较无显著差异(P>0.05)。结论早期应用依达拉奉,可明显提高rt-PA静脉溶栓治疗急性脑梗死的疗效,有效预防HT发生,其增强疗效作用可能与显著降低Hcy、S100β蛋白、ET-1水平有关。
Objective To explore the effect of edaravone on acute cerebral infarction treated by rt-PA intravenous thrombolysis. Methods 160 cases with acute cerebral infarction were selected and randomly divided into the control group and the observation group, 80 cases in each group. Control group was given nicholin treatment and observation group was given edaravone. The two groups were all given treatment of rt-PA intravenous thrombolysis. Before treatment and 2 weeks after treatment, NIHSS score and BI score were measured; Hcy, S100β protein, ET-1 level of the two groups were tested;HT occurrence and adverse reactions of the two groups were observed. Results NIHSS score of observation group was obviously lower than that in the control group two weeks after treatment(P<0.05), BI score was obviously increased(P<0.05);Hcy, S100β protein, ET-1 levels of observation group declined more obviously than control group(P<0.05); HT occurrence rate of observation group declined obviously than that in control group(P<0.05); incidence of side effect of the two groups had no statistic significance(P>0.05). Conclusion Edaravone early application can improve curative effect of acute cerebral infarction treated by rt-PA intravenous thrombolysis, prevent occurrence of HTand its effect may related to significant declination of Hcy, S100β protein, ET-1 level.
引文
[1]张鹏,高志强,孙高慧,等.低剂量尿激酶与重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死的疗效[J].中国实用神经疾病杂志, 2013, 16(24):4-6.
[2]赵秀欣,穆利春,马丽芳. rt-PA静脉溶栓治疗急性脑梗死临床分析[J].中国循证心血管医学杂志, 2016, 8(4):486-488.
[3]毕庆国,刘春兰,付建辉,等. rt-PA静脉溶栓联合高压氧治疗急性脑梗死的效果观察[J].国外医学医学地理分册, 2015, 36(1):51-54.
[4]兰荣,田文生.依达拉奉联合rt-PA时间窗内静脉溶栓治疗急性脑梗死的效果观察[J].世界最新医学信息文摘:连续型电子期刊,2015, 15(22):128-129.
[5]夏成才,喻丽芝,彭明强.脑电图对急性脑梗死早期诊断价值的研究[J].卒中与神经疾病, 2013, 20(3):176-177.
[6]杨继党,林清原.静脉溶栓对合并脑微出血的急性脑梗死后出血性转化的影响[J].实用医学杂志, 2013, 29(11):1785-1787.
[7]杨江胜,朱祖福,张剑宇,等.小剂量rt-PA静脉溶栓治疗急性脑梗死临床分析[J].脑与神经疾病杂志, 2013, 21(2):88-90.
[8]李欣,李雯,刘凌云.依达拉奉联合rt-PA超时间窗静脉溶栓治疗急性脑梗死的疗效[J].中国老年学, 2013, 33(14):3287-3288.
[9]陈阳,程英平,李清华,等.依达拉奉联合重组组织型纤溶酶原激活剂治疗脑梗死的疗效[J].贵阳医学院学报, 2016, 41(1):103-105.
[10]何伟.脑卒中患者血清HCY、IL-10及MMP-9水平与脑梗死体积的关系[J].心血管康复医学杂志, 2013, 22(5):439-442.
[11]潘丹红,瞿笑丰,沈燕.依达拉奉联合rt-PA治疗对脑梗死患者的抗心磷脂抗体、内皮素-1和D-二聚体的影响[J].临床和实验医学杂志, 2014,13(9):702-705.
[12]张莉峰,肖悠美,王爱丽.依达拉奉对急性脑梗死患者rt-PA静脉溶栓后MMP-9表达及出血性转化的影响[J].中国急救医学,2016, 36(10):913-917.
